Company / Cash & Equivalents
Organogenesis Holdings Inc. Cash & Equivalents History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$93.7M
FY2025
5-year range
$93.7M / $135.6M
FY2021-FY2025
Trend
-30.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $104M to $94M over the past 2 years.
Based on SEC 10-K filings.
$94M in FY2025 with a 3-year CAGR of -2.9%.
Declined from $104M to $94M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -2.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -2.9%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 30.9% year-over-year.
- Peak cash & equivalents was recorded in FY2024.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $93.7M | -30.9% |
| FY2024 | $135.6M | +30.6% |
| FY2023 | $103.8M | +1.3% |
| FY2022 | $102.5M | -10.1% |
| FY2021 | $113.9M | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026